[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341788-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341788-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","axl-expression-reflects-tumor-immune-cell-dynamics-impacting-outcome-in-non-small-cell-lung-cancer-patients-treated-with-immune-checkpoint-inhibitor-monotherapy","AXL expression reﬂects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy","","AXL receptor expression is examined as a proposed driver of immune-checkpoint inhibitor (ICI) resistance in non-small cell lung cancer (NSCLC). Tumor samples from 111 ICI-monotherapy–treated patients were profiled for tumor and immune AXL by immunohistochemistry, with subsets analyzed by whole-exome sequencing and imaging mass cytometry. Tumor-cell AXL linked to aggressive features yet showed improved disease control in PD-L1 high first-line patients; AXL+ immune infiltration correlated with better overall outcomes, supporting AXL-inhibitor combination strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/axl-expression-reflects-tumor-immune-cell-dynamics-impacting-outcome-in-non-small-cell-lung-cancer-patients-treated-with-immune-checkpoint-inhibitor-monotherapy/341788/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/axl-expression-reflects-tumor-immune-cell-dynamics-impacting-outcome-in-non-small-cell-lung-cancer-patients-treated-with-immune-checkpoint-inhibitor-monotherapy/341788.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the central question of the study on AXL in NSCLC?","Question",{"text":63,"@type":64},"Whether AXL expression relates to tumor-immune cell dynamics that predict outcomes in NSCLC patients treated with immune checkpoint inhibitor monotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were AXL expression and immune context assessed in the patients?",{"text":68,"@type":64},"Tumor and immune AXL were measured by immunohistochemistry, and subsets were further analyzed using whole-exome sequencing and imaging mass cytometry, then linked to ICI outcome measures.",{"name":70,"@type":61,"acceptedAnswer":71},"What associations did the study find between tumor-cell AXL and clinical outcomes?",{"text":72,"@type":64},"Tumor-cell AXL correlated with aggressive phenotypic features and reduced overall survival after chemotherapy progression, but it also associated with improved disease control in ICI-treated PD-L1 high first-line patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341788,1790927313,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Original Research PUBLISHED 21 August 2024  \nDOI 10.3389/fimmu.2024.1444007  \nOPEN ACCESS  \nEDITED BY  \nArumugam Jayakumar,  \nUniversity of Texas MD Anderson Cancer Center, United States  \nREVIEWED BY  \nKenji Morimoto,  \nKyoto Prefectural University of Medicine, Japan  \nDouglas K. Graham,  \nEmory University, United States  \n*CORRESPONDENCE Fabian Gärtner  \n [fabgartner1@gmail.com](fabgartner1@gmail.com);  \n [fabian.gartner@student.uib. no](fabian.gartner@student.uib. no)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 04 June 2024  \nACCEPTED 01 August 2024  \nPUBLISHED 21 August 2024  \nCITATION  \nRayford A, Gärtner F, Ramnefjell MP, Lorens JB, Micklem DR, Aanerud M and Engelsen AST (2024) AXL expression reﬂects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.  \nFront. Immunol. 15:1444007 .  \ndoi: 10.3389/fimmu.2024.1444007  \nCOPYRIGHT  \n© 2024 Rayford, Gärtner, Ramnefjell, Lorens, Micklem, Aanerud and Engelsen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAXL expression reﬂects tumorimmune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint  \ninhibitor monotherapy  \nAustin Rayford 1†, Fabian Gärtner 2,3*†, Maria P. Ramnefjell 4,5, James B. Lorens 1, David R. Micklem 6, Marianne Aanerud 2,3 and Agnete S. T. Engelsen 1,5  \n1 Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen,  \nBergen, Norway, 2 Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway,  \n3 Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway,  \n4 Department of Pathology, Haukeland University Hospital, Bergen, Norway, 5 Department of Clinical Medicine and Centre for Cancer Biomarkers, Faculty of Medicine, University of Bergen, Bergen, Norway, 6 BerGenBio ASA, Bergen, Norway  \nIntroduction: AXL receptor expression is proposed to confer immunecheckpoint inhibitor (ICI)-resistance in non-small cell lung cancer (NSCLC) patients. We sought to interrogate AXL expression in conjunction with mutational and tumor-microenvironmental features to uncover predictive mechanisms of resistance in ICI-treated NSCLC patients.  \nMethods: Tumor samples from 111 NSCLC patients treated with ICImonotherapy were analyzed by immunohistochemistry for tumor- and immune-AXL expression. Subsets of patients were analyzed by whole-exome sequencing (n = 44) and imaging mass cytometry (n = 14) . Results were related to ICI-outcome measurements.  \nResults: Tumor-cell AXL expression correlated with aggressive phenotypic features including reduced OS in patients treated with ICIs (P = 0 . 04) after chemotherapy progression, but conversely associated with improved disease control (P = 0 . 045) in ICI-treated, PD-L1 high ﬁrst-line patients. AXL+ immunecell inﬁltration correlated with total immune-cell inﬁltration and improved overall outcomes (PFS: P = 0 . 044, OS: P = 0 . 054) . Tumor-cell AXL-upregulation showed enrichment in mutations associated with PD-L1-upregulation and ICI-response such as MUC4 and ZNF469, as well as adverse mutations including CSMD1 and LRP1B which associated with an immune-suppressed tumor phenotype and poor ICI prognosis particularly within chemotherapy-treated patients. Tumor mutational burden had no effect on ICI-outcomes and was associated with a lack of tumor-inﬁltrating immune cells. Spatial-immunophenotyping provided evidence that tumor-cell AXL-upregulation and adverse mutations modulate the tumor","cbCaiuRK5kJfUnC7","https://ap.wps.com/l/cbCaiuRK5kJfUnC7","pdf",5583371,15,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the central question of the study on AXL in NSCLC?\",\"answer\":\"Whether AXL expression relates to tumor-immune cell dynamics that predict outcomes in NSCLC patients treated with immune checkpoint inhibitor monotherapy.\"},{\"question\":\"How were AXL expression and immune context assessed in the patients?\",\"answer\":\"Tumor and immune AXL were measured by immunohistochemistry, and subsets were further analyzed using whole-exome sequencing and imaging mass cytometry, then linked to ICI outcome measures.\"},{\"question\":\"What associations did the study find between tumor-cell AXL and clinical outcomes?\",\"answer\":\"Tumor-cell AXL correlated with aggressive phenotypic features and reduced overall survival after chemotherapy progression, but it also associated with improved disease control in ICI-treated PD-L1 high first-line patients.\"}]","AXL expression reﬂects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy | PDF",1790043816,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7ea9801c47f7bea79173d5f11837d66.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4207cec7d3b0bfbaba4314c798cf7f7f.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c87a3628c1119bb186eb7c52cd93afe.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/232eb2d2e967b788fcfa80adbfd4b5de.webp",980,1385]